GNVR — Genvor Share Price
Last trade - 00:00- $45.46m
- $46.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genvor Incorporated is a developer of sustainable plant health solutions, with a portfolio of patented peptides to provide crops with anti-pathogen and enhanced nutritional properties through biological foliar application as well as transgenic seed traits. The Company leverages its licensing-first business model with active trait developments for a variety of crops including corn, citrus, rice, cotton, soybean, flax and potato. Its solutions are designed to fight debilitating and deadly plant diseases, such as bacteria and fungi, in a broad spectrum of crop types through its library of patented anti-microbial peptides (AMPs). These AMPs can be applied to plants in the form of non-chemical seed traits (Transgenic seed traits), which imbue seeds with the desired traits, allowing plants to naturally produce AMPs, as well as a topical spray (Bio-pesticide) application.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 18th, 2019
- Public Since
- September 1st, 2023
- No. of Shareholders
- 167
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 20,204,608
- Address
- 1550 W Horizon Ridge Pkwy, Ste R #3040, HENDERSON, 89012
- Web
- https://www.genvor.com/
- Phone
- +1 2144271921
- Auditors
- Turner, Stone & Company
Similar to GNVR
Adia Nutrition
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
AiXin Life International
Pink Sheets on Nasdaq
FAQ
As of Today at 20:51 UTC, shares in Genvor are trading at $1.00. This share price information is delayed by 15 minutes.
Shares in Genvor last closed at $1.00 and the price had moved by over the past 365 days. In terms of relative price strength the Genvor share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Genvor does not currently pay a dividend.
Genvor does not currently pay a dividend.
Genvor does not currently pay a dividend.
To buy shares in Genvor you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.00, shares in Genvor had a market capitalisation of $20.20m.
Here are the trading details for Genvor:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GNVR
Based on an overall assessment of its quality, value and momentum Genvor is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genvor. Over the past six months, its share price has underperformed the S&P500 Index by -77.36%.
As of the last closing price of $1.00, shares in Genvor were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genvor PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genvor's directors